<?xml version="1.0" encoding="UTF-8"?>
<svg height="746.5" width="548.58" xmlns="http://www.w3.org/2000/svg">
 <g>
  <text svgx:width="0.48,0.48,0.17,0.55,0.46,0.52,0.29,0.44,0.53,0.54,0.53,0.3,0.3,0.55,0.5,0.46,0.17,0.55,0.5,0.53,0.21,0.48,0.55,0.53,0.26,0.55,0.48,0.53,0.54,0.53,0.3,0.53,0.48,0.21,0.21,0.52,0.81,0.55,0.21,0.53,0.55,0.29,0.48,0.36,0.54,0.53,0.53,0.36,0.48,0.36,0.55,0.53,0.26,0.55,0.45,0.45,0.36,0.44,0.52,0.21,0.45,0.29,0.55,0.36,0.81,0.53,0.53,0.3,0.53,0.55,0.81,0.52,0.36,0.44,0.21,0.48,0.17" y="95.4" x="56.7,60.1,63.5,64.8,71.7,75.0,78.7,80.8,83.9,87.7,91.5,95.3,97.4,99.7,101.7,105.3,108.5,109.8,111.9,115.4,119.2,120.7,124.3,126.3,130.0,132.0,134.0,137.4,141.2,145.1,148.9,151.0,154.8,158.2,159.7,161.2,164.9,170.9,172.8,174.3,178.3,180.2,182.3,185.7,188.3,192.2,195.9,199.7,202.3,205.7,208.4,210.5,214.3,216.2,218.3,221.5,224.6,227.2,230.3,234.0,235.5,238.7,240.9,242.9,245.5,251.3,255.1,258.9,261.0,265.0,267.0,272.7,276.5,279.0,282.2,283.6,287.1" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">85. Furchgott RF. Role of endothelium in responses of vascular smooth muscle.</text>
  <text svgx:width="0.56,0.21,0.29,0.44,0.55,0.5,0.48,0.36,0.17,0.55,0.48,0.48,0.48,0.48,0.17,0.48,0.48,0.26,0.48,0.26,0.17,0.48,0.48,0.48" y="104.3" x="71.7,75.7,77.2,79.3,82.6,84.5,88.1,91.5,94.1,95.4,97.4,100.8,104.2,107.6,111.0,112.2,115.6,119.1,120.9,124.3,126.2,127.4,130.8,134.2" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">Circ Res. 1983;53(5):557</text>
  <text svgx:width="0.5" y="104.3" x="137.6" style="fill:rgb(19,20,19);font-family:PmpdftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">–</text>
  <text svgx:width="0.48,0.48,0.17" y="104.3" x="141.2,144.6,148.0" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">73.</text>
  <text svgx:width="0.48,0.48,0.17,0.55,0.46,0.52,0.29,0.44,0.53,0.54,0.53,0.3,0.3,0.55,0.5,0.46,0.17,0.55,0.53,0.45,0.72,0.45,0.54,0.4,0.42,0.21,0.55,0.34,0.5,0.17,0.55,0.46,0.53,0.48,0.55,0.53,0.54,0.21,0.21,0.54,0.45,0.3,0.53,0.29,0.44,0.55,0.29,0.53,0.21,0.48,0.55,0.53,0.26,0.55,0.48,0.53,0.54,0.53,0.3,0.53,0.48,0.21,0.21,0.45,0.21,0.55,0.44,0.48,0.21,0.21,0.36,0.55,0.21,0.53,0.55,0.3,0.53,0.48" y="113.3" x="56.7,60.1,63.5,64.8,71.7,75.0,78.7,80.8,83.9,87.7,91.5,95.3,97.4,99.7,101.7,105.3,108.5,109.8,111.9,115.6,118.8,123.9,127.1,131.0,133.8,136.8,138.3,140.4,142.9,146.4,147.7,149.8,153.0,156.8,160.4,162.4,166.2,170.0,171.5,173.0,176.8,180.0,182.2,185.9,188.0,191.3,193.3,195.3,199.1,200.6,204.2,206.2,210.0,211.9,214.0,217.4,221.2,225.0,228.8,230.9,234.7,238.1,239.6,241.1,244.3,245.9,247.9,251.0,254.4,255.9,257.4,260.1,262.1,263.6,267.6,269.5,271.7,275.4" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">86. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the</text>
  <text svgx:width="0.29,0.48,0.21,0.45,0.43,0.45,0.3,0.21,0.53,0.53,0.55,0.53,0.26,0.55,0.45,0.29,0.3,0.48,0.29,0.21,0.45,0.21,0.55,0.36,0.81,0.53,0.53,0.3,0.53,0.55,0.81,0.52,0.36,0.44,0.21,0.48,0.55,0.54,0.44,0.55,0.45,0.44,0.48,0.3,0.44,0.21,0.44,0.53,0.53,0.21,0.21,0.53,0.48,0.17,0.55,0.63,0.45,0.3,0.52,0.29,0.48,0.17,0.55,0.48,0.48,0.48,0.48,0.17" y="122.3" x="71.7,73.8,77.2,78.7,81.9,84.9,88.1,90.2,91.7,95.5,99.5,101.4,105.2,107.2,109.2,112.4,114.4,116.6,120.0,122.1,123.6,126.8,128.3,130.4,133.0,138.8,142.6,146.3,148.5,152.5,154.4,160.2,163.9,166.5,169.6,171.1,174.7,176.7,180.5,183.8,185.8,189.0,192.1,195.5,197.6,200.8,202.2,205.4,209.1,212.9,214.4,215.9,219.7,223.1,224.4,226.4,231.0,234.1,236.3,240.0,242.1,245.5,246.8,248.8,252.2,255.6,259.1,262.5" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;</text>
  <text svgx:width="0.48,0.48,0.48,0.26,0.48,0.48,0.48,0.48,0.26,0.17,0.48,0.48,0.48" y="131.4" x="71.7,75.1,78.5,82.0,83.8,87.2,90.6,94.0,97.5,99.3,100.5,103.9,107.3" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">288(5789):373</text>
  <text svgx:width="0.5" y="131.4" x="110.7" style="fill:rgb(19,20,19);font-family:PmpdftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">–</text>
  <text svgx:width="0.48,0.48,0.17" y="131.4" x="114.3,117.7,121.1" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">76.</text>
  <text svgx:width="0.48,0.48,0.17,0.55,0.63,0.45,0.29,0.45,0.48,0.44,0.55,0.5,0.64,0.17,0.55,0.77,0.52,0.36,0.44,0.45,0.29,0.21,0.53,0.21,0.44,0.55,0.29,0.48,0.44,0.48,0.54,0.3,0.53,0.29,0.55,0.45,0.54,0.53,0.53,0.21,0.36,0.3,0.36,0.55,0.45,0.53,0.54,0.55,0.45,0.53,0.3,0.45,0.54,0.53,0.53,0.21,0.36,0.3,0.36,0.17,0.55,0.48,0.26,0.26,0.48,0.44,0.3,0.36,0.55,0.53,0.53" y="140.3" x="56.7,60.1,63.5,64.8,71.7,76.2,79.4,81.4,84.6,88.0,91.3,93.3,96.8,101.4,102.7,104.8,110.3,114.0,116.6,119.7,122.9,124.9,126.4,130.2,131.7,135.0,136.9,139.0,142.4,145.5,148.9,152.8,154.9,158.7,160.9,162.9,166.1,170.0,173.8,177.5,179.0,181.6,183.8,186.5,188.6,191.7,195.5,199.6,201.5,204.7,208.5,210.6,213.8,217.6,221.4,225.2,226.7,229.3,231.4,234.0,235.3,237.4,240.8,242.7,244.5,248.0,251.1,253.2,255.9,257.9,261.7" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">87. Harvey RD. Muscarinic receptor agonists and antagonists: effects on</text>
  <text svgx:width="0.44,0.45,0.29,0.54,0.21,0.53,0.45,0.45,0.36,0.44,0.52,0.21,0.45,0.29,0.55,0.26,0.52,0.53,0.44,0.3,0.21,0.53,0.53,0.17,0.55,0.21,0.53,0.17,0.55,0.77,0.52,0.36,0.44,0.45,0.29,0.21,0.53,0.21,0.44,0.55,0.5,0.48,0.44,0.48,0.54,0.3,0.53,0.29,0.36,0.17,0.55,0.48,0.48,0.48,0.17,0.55,0.63,0.48,0.72,0.55,0.5,0.53,0.29,0.42,0.17,0.55,0.46,0.54,0.29,0.21,0.53,0.54,0.48,0.29,0.17" y="149.3" x="71.7,74.8,78.0,80.1,83.9,85.4,89.2,92.4,95.6,98.2,101.3,105.0,106.5,109.7,111.8,113.9,115.7,119.5,123.2,126.3,128.5,130.0,133.8,137.6,138.8,140.9,142.4,146.1,147.4,149.5,155.0,158.7,161.3,164.4,167.6,169.7,171.1,174.9,176.4,179.7,181.6,185.2,188.6,191.7,195.1,199.0,201.1,204.9,207.0,209.6,210.9,212.9,216.3,219.8,223.2,224.4,226.5,231.0,234.4,239.8,241.7,245.2,249.0,251.1,254.1,255.3,257.4,260.7,264.6,266.6,268.1,271.9,275.7,279.2,281.2" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">cardiovascular function. In: Muscarinic Receptors, 208. New York: Springer;</text>
  <text svgx:width="0.48,0.48,0.48,0.48,0.17,0.55,0.54,0.17,0.55,0.48,0.48,0.48" y="158.3" x="71.7,75.1,78.5,82.0,85.4,86.6,88.7,92.5,93.8,95.9,99.3,102.7" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">2012. p. 299</text>
  <text svgx:width="0.5" y="158.3" x="106.1" style="fill:rgb(19,20,19);font-family:PmpdftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">–</text>
  <text svgx:width="0.48,0.48,0.48,0.17" y="158.3" x="109.6,113.1,116.5,119.9" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">316.</text>
  <text svgx:width="0.48,0.48,0.17,0.55,0.49,0.53,0.54,0.21,0.53,0.44,0.53,0.45,0.45,0.55,0.34,0.17,0.55,0.5,0.52,0.4,0.36,0.48,0.29,0.53,0.45,0.45,0.55,0.58,0.17,0.55,0.5,0.48,0.29,0.53,0.45,0.3,0.53,0.45,0.45,0.55,0.21,0.17,0.55,0.5,0.21,0.53,0.44,0.53,0.48,0.81,0.21,0.44,0.45,0.21,0.55,0.45,0.36,0.54,0.48,0.44,0.3,0.36,0.55,0.53,0.26,0.55,0.53,0.21,0.3,0.29,0.21,0.44,0.55,0.53,0.43,0.21,0.54,0.48" y="167.4" x="56.7,60.1,63.5,64.8,71.7,75.2,78.8,82.5,84.0,87.6,90.8,94.3,97.5,100.9,102.5,104.8,106.1,107.9,111.4,115.0,117.8,120.2,123.6,125.5,129.3,132.3,135.6,137.3,141.5,142.7,144.4,148.0,151.2,153.3,156.9,160.1,162.0,165.8,168.8,172.2,173.9,175.2,176.5,178.2,181.8,183.1,186.9,189.9,193.6,196.8,202.6,204.0,207.1,210.1,211.7,213.4,216.6,219.0,222.7,226.2,229.1,231.2,233.9,235.6,239.4,241.3,243.0,246.8,248.1,250.2,252.1,253.6,256.9,258.5,262.2,265.1,266.6,270.3" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">88. Kopincová J, Púzserová A, Bernátová I. Biochemical aspects of nitric oxide</text>
  <text svgx:width="0.36,0.44,0.53,0.3,0.53,0.45,0.36,0.48,0.55,0.26,0.48,0.48,0.54,0.54,0.45,0.44,0.42,0.55,0.29,0.48,0.54,0.52,0.21,0.45,0.3,0.21,0.53,0.53,0.55,0.54,0.44,0.55,0.53,0.21,0.3,0.29,0.21,0.44,0.55,0.53,0.43,0.21,0.54,0.48,0.17,0.55,0.21,0.53,0.3,0.48,0.29,0.54,0.21,0.36,0.44,0.21,0.54,0.55,0.46,0.53,0.43,0.21,0.44,0.53,0.21,0.17,0.55,0.48,0.48,0.48,0.48,0.17,0.48,0.26,0.48,0.26,0.17,0.48,0.48" y="176.3" x="71.7,74.3,77.2,81.0,83.0,86.8,89.8,92.4,96.0,97.5,99.4,102.6,106.0,109.7,113.4,116.6,119.6,122.8,124.4,126.5,129.7,133.5,137.2,138.5,141.6,143.7,145.0,148.8,152.8,154.4,158.1,161.4,163.0,166.8,168.2,170.3,172.2,173.6,176.9,178.5,182.3,185.2,186.6,190.4,193.7,194.9,196.7,198.1,201.9,203.9,207.2,209.2,212.9,214.3,216.9,219.9,221.2,225.3,226.9,230.2,233.8,236.8,238.2,241.3,244.9,246.3,247.6,249.3,252.7,255.9,259.3,262.5,263.7,267.0,268.8,272.1,273.9,275.0,278.3" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">synthase feedback regulation by nitric oxide. Interdiscip Toxicol. 2011;4(2):63</text>
  <text svgx:width="0.5" y="176.3" x="281.6" style="fill:rgb(19,20,19);font-family:PmpdftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">–</text>
  <text svgx:width="0.48,0.17" y="176.3" x="285.1,288.5" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">8.</text>
  <text svgx:width="0.48,0.48,0.17,0.55,0.46,0.36,0.45,0.21,0.55,0.46,0.34,0.17,0.55,0.49,0.45,0.36,0.36,0.55,0.64,0.58,0.17,0.55,0.56,0.44,0.44,0.21,0.21,0.44,0.55,0.61,0.77,0.5,0.55,0.36,0.21,0.54,0.53,0.45,0.21,0.21,0.53,0.54,0.55,0.21,0.53,0.55,0.44,0.45,0.29,0.54,0.21,0.53,0.45,0.45,0.36,0.44,0.52,0.21,0.45,0.29,0.55,0.54,0.45,0.3,0.53,0.53,0.54,0.53,0.44,0.36,0.21,0.53,0.21,0.53,0.54,0.44" y="185.3" x="56.7,60.1,63.5,64.8,71.7,75.0,77.6,80.8,82.3,84.4,87.6,90.1,91.3,93.4,96.9,100.1,102.7,105.4,107.4,112.0,116.2,117.5,119.5,123.5,126.6,129.7,131.2,132.7,136.0,137.9,142.3,147.8,151.5,153.5,156.1,157.6,161.5,165.2,168.4,169.9,171.4,175.2,179.2,181.2,182.7,186.6,188.6,191.7,194.9,196.9,200.8,202.3,206.0,209.2,212.4,215.0,218.1,221.8,223.3,226.5,228.7,230.8,234.6,237.8,240.0,243.8,247.6,251.4,255.2,258.3,260.9,262.4,266.2,267.6,271.4,275.3" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">89. Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology</text>
  <text svgx:width="0.45,0.53,0.54,0.55,0.3,0.53,0.48,0.29,0.45,0.54,0.48,0.52,0.3,0.21,0.44,0.36,0.17,0.55,0.5,0.53,0.45,0.29,0.81,0.45,0.44,0.53,0.21,0.55,0.46,0.53,0.48,0.29,0.17,0.55,0.48,0.48,0.48,0.48,0.17,0.48,0.48,0.48,0.26,0.48,0.26,0.17,0.48,0.48,0.48" y="194.3" x="71.7,74.9,78.7,82.7,84.6,86.8,90.6,94.0,96.1,99.2,103.1,106.5,110.2,112.4,113.9,117.0,119.6,120.8,122.9,126.5,130.3,133.4,135.5,141.3,144.5,147.6,151.4,153.0,155.1,158.3,162.1,165.5,167.6,168.9,170.9,174.3,177.7,181.1,184.5,185.7,189.1,192.5,195.9,197.8,201.2,203.1,204.2,207.7,211.1" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">and therapeutics. Pharmacol Ther. 2009;122(3):216</text>
  <text svgx:width="0.5" y="194.3" x="214.5" style="fill:rgb(19,20,19);font-family:PmpdftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">–</text>
  <text svgx:width="0.48,0.48,0.17" y="194.3" x="218.1,221.5,224.9" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">38.</text>
  <text svgx:width="0.48,0.48,0.17,0.55,0.61,0.21,0.21,0.48,0.36,0.55,0.46,0.64,0.17,0.55,0.46,0.45,0.53,0.54,0.48,0.29,0.55,0.61,0.46,0.17,0.55,0.63,0.53,0.36,0.36,0.45,0.81,0.45,0.53,0.55,0.5,0.64,0.17,0.55,0.49,0.45,0.54,0.53,0.72,0.21,0.3,0.4,0.55,0.5,0.34,0.17,0.55,0.21,0.81,0.54,0.45,0.21,0.29,0.48,0.54,0.55,0.45,0.45,0.36,0.53,0.54,0.21,0.21,0.45,0.3,0.21,0.53,0.53,0.55,0.21,0.53" y="203.4" x="56.7,60.1,63.5,64.8,71.7,76.1,77.6,79.1,82.5,85.2,87.2,90.5,95.1,96.3,98.4,101.6,104.8,108.6,112.4,115.9,118.0,120.1,124.4,127.7,129.0,131.1,135.6,139.4,142.0,144.6,147.8,153.5,156.7,160.7,162.7,166.2,170.8,172.1,174.2,177.6,180.8,184.7,188.5,193.6,195.1,197.2,200.2,202.2,205.7,208.2,209.4,211.5,213.0,218.8,222.6,225.8,227.3,229.4,232.8,236.8,238.8,242.0,245.2,247.8,251.5,255.4,256.9,258.4,261.5,263.7,265.2,269.0,272.9,274.9,276.4" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">90. Giles TD, Sander GE, Nossaman BD, Kadowitz PJ. Impaired vasodilation in</text>
  <text svgx:width="0.3,0.53,0.48,0.55,0.54,0.45,0.3,0.53,0.53,0.54,0.48,0.53,0.48,0.36,0.21,0.36,0.55,0.53,0.26,0.55,0.53,0.44,0.54,0.48,0.29,0.3,0.48,0.53,0.36,0.21,0.53,0.53,0.17,0.55,0.26,0.53,0.44,0.52,0.36,0.55,0.53,0.53,0.55,0.53,0.21,0.3,0.29,0.21,0.44,0.55,0.53,0.43,0.21,0.54,0.48,0.17,0.55,0.48,0.53,0.54,0.53,0.3,0.53,0.48,0.21,0.21,0.45,0.21" y="212.3" x="71.7,73.9,77.7,81.3,83.2,87.0,90.2,92.4,96.1,99.9,103.8,107.2,111.0,114.4,117.0,118.5,121.2,123.2,127.0,129.0,131.0,134.8,137.9,141.8,145.2,147.3,149.4,152.8,156.6,159.2,160.7,164.5,168.2,169.5,171.6,173.4,177.2,180.3,184.0,186.7,188.8,192.6,196.5,198.5,202.3,203.7,205.9,208.0,209.5,212.8,214.7,218.5,221.5,223.0,226.9,230.3,231.5,233.6,237.0,240.8,244.7,248.5,250.6,254.4,257.8,259.3,260.8,264.0" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">the pathogenesis of hypertension: focus on nitric oxide, endothelial</text>
  <text svgx:width="0.32" y="212.3" x="265.4" style="fill:rgb(19,20,19);font-family:PmpdftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">‐</text>
  <text svgx:width="0.54,0.48,0.29,0.21,0.45,0.48,0.54" y="212.3" x="267.8,271.6,275.0,277.1,278.6,281.8,285.2" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">derived</text>
  <text svgx:width="0.53,0.44,0.54,0.48,0.29,0.54,0.53,0.21,0.45,0.29,0.21,0.4,0.21,0.53,0.54,0.55,0.26,0.45,0.44,0.3,0.53,0.29,0.36,0.17,0.55,0.45,0.53,0.54,0.55,0.54,0.29,0.53,0.36,0.3,0.45,0.54,0.21,0.45,0.53,0.54,0.21,0.53,0.36,0.17,0.55,0.34,0.55,0.56,0.21,0.21,0.53,0.55,0.63,0.44,0.54,0.48,0.29,0.3,0.48,0.53,0.36,0.17,0.55,0.48,0.48,0.48,0.48,0.17,0.48,0.48,0.26,0.48,0.26,0.17" y="221.3" x="71.7,75.5,78.6,82.5,85.9,88.0,91.8,95.6,97.1,100.3,102.3,103.8,106.6,108.1,111.9,115.9,117.9,119.8,123.0,126.1,128.2,132.0,134.1,136.7,137.9,140.0,143.2,146.9,151.0,153.0,156.8,158.9,162.7,165.3,167.4,170.6,174.5,175.9,179.1,182.9,186.8,188.2,192.0,194.6,195.9,198.0,200.5,202.6,206.6,208.0,209.5,213.5,215.4,219.9,223.0,226.9,230.3,232.3,234.5,237.9,241.7,244.3,245.6,247.6,251.0,254.5,257.9,261.3,262.5,265.9,269.3,271.1,274.6,276.4" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">hyperpolarizing factors, and prostaglandins. J Clin Hypertens. 2012;14(4):</text>
  <text svgx:width="0.48,0.48,0.48" y="230.3" x="71.7,75.1,78.5" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">198</text>
  <text svgx:width="0.5" y="230.3" x="81.9" style="fill:rgb(19,20,19);font-family:PmpdftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">–</text>
  <text svgx:width="0.48,0.48,0.48,0.17" y="230.3" x="85.5,88.9,92.3,95.7" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">205.</text>
  <text svgx:width="0.48,0.48,0.17,0.55,0.5,0.45,0.29,0.42,0.21,0.53,0.54,0.3,0.53,0.53,0.55,0.63,0.56,0.17,0.55,0.56,0.53,0.21,0.48,0.81,0.45,0.53,0.55,0.63,0.58,0.17,0.55,0.46,0.45,0.29,0.48,0.55,0.77,0.17,0.55,0.5,0.29,0.53,0.36,0.3,0.45,0.44,0.44,0.44,0.21,0.21,0.53,0.55,0.45,0.53,0.54,0.55,0.48,0.53,0.54,0.53,0.3,0.53,0.48,0.21,0.21,0.52,0.81,0.29,0.54,0.48,0.54,0.48,0.53,0.54,0.48,0.53,0.3" y="239.4" x="56.7,60.1,63.5,64.8,71.7,75.3,78.2,80.3,83.1,84.6,88.2,92.0,94.1,97.7,101.7,103.4,107.8,111.6,112.9,114.6,118.6,122.3,123.6,127.1,132.7,135.8,139.8,141.4,145.8,149.8,151.1,152.8,156.1,159.1,161.2,164.8,166.3,171.8,173.1,174.8,178.3,180.2,184.0,186.4,188.6,191.6,194.7,197.6,200.7,202.1,203.5,207.5,209.1,212.1,215.9,220.0,221.6,225.0,228.6,232.3,236.1,238.1,241.9,245.1,246.6,247.9,251.5,257.3,259.2,262.9,266.4,270.0,273.4,277.1,280.9,284.1,287.9" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">91. Parkington HC, Coleman HA, Tare M. Prostacyclin and endothelium-dependent</text>
  <text svgx:width="0.53,0.44,0.54,0.48,0.29,0.54,0.53,0.21,0.45,0.29,0.21,0.4,0.45,0.3,0.21,0.53,0.53,0.17,0.55,0.5,0.53,0.45,0.29,0.81,0.45,0.44,0.53,0.21,0.55,0.5,0.48,0.36,0.17,0.55,0.48,0.48,0.48,0.48,0.17,0.48,0.48,0.26,0.48,0.26,0.17,0.48,0.48,0.48" y="248.3" x="71.7,75.5,78.4,82.3,85.5,87.6,91.3,95.1,96.3,99.5,101.4,102.9,105.6,108.7,110.7,112.1,115.9,119.5,120.8,122.5,126.1,129.7,132.8,134.8,140.5,143.5,146.7,150.3,151.9,153.6,157.1,160.4,163.0,164.3,165.9,169.2,172.6,175.9,179.3,180.3,183.7,187.0,188.8,192.0,193.9,194.9,198.2,201.6" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">hyperpolarization. Pharmacol Res. 2004;49(6):509</text>
  <text svgx:width="0.5" y="248.3" x="204.9" style="fill:rgb(19,20,19);font-family:PmpdftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">–</text>
  <text svgx:width="0.48,0.48,0.17" y="248.3" x="208.3,211.6,215.0" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">14.</text>
  <text svgx:width="0.48,0.48,0.17,0.55,0.46,0.53,0.54,0.48,0.44,0.55,0.56,0.61,0.17,0.55,0.5,0.53,0.3,0.45,0.36,0.36,0.21,0.52,0.81,0.55,0.44,0.53,0.45,0.53,0.53,0.48,0.21,0.55,0.26,0.52,0.53,0.44,0.3,0.21,0.53,0.53,0.55,0.21,0.53,0.55,0.45,0.45,0.36,0.44,0.52,0.21,0.45,0.29,0.55,0.54,0.21,0.36,0.48,0.45,0.36,0.48,0.17,0.55,0.58,0.29,0.3,0.48,0.29,0.21,0.53,0.36,0.44,0.21,0.48,0.29" y="257.3" x="56.7,60.1,63.5,64.8,71.7,75.0,78.8,82.6,86.0,89.3,91.3,95.3,99.7,100.9,103.0,106.5,110.3,112.5,115.6,118.2,120.8,122.3,126.0,132.1,134.0,137.1,140.9,144.0,147.8,151.6,155.0,156.6,158.7,160.5,164.2,168.0,171.1,173.3,174.8,178.6,182.5,184.5,186.0,189.9,191.8,195.0,198.2,200.8,203.9,207.6,209.1,212.3,214.5,216.6,220.4,221.9,224.5,227.9,231.1,233.7,237.1,238.4,240.4,244.6,246.7,248.8,252.2,254.3,255.8,259.6,262.2,265.3,266.8,270.2" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">92. Sobey CG. Potassium channel function in vascular disease. Arterioscler</text>
  <text svgx:width="0.46,0.53,0.29,0.53,0.81,0.54,0.55,0.5,0.45,0.36,0.44,0.55,0.5,0.21,0.53,0.21,0.17,0.55,0.48,0.48,0.48,0.48,0.17,0.48,0.48,0.26,0.48,0.26,0.17,0.48,0.48" y="266.3" x="71.7,75.0,78.8,80.8,84.6,90.4,94.5,96.4,99.9,103.1,105.7,109.0,111.0,114.6,116.0,119.8,121.3,122.6,124.6,128.0,131.4,134.8,138.3,139.4,142.9,146.3,148.1,151.5,153.4,154.6,158.0" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">Thromb Vasc Biol. 2001;21(1):28</text>
  <text svgx:width="0.5" y="266.3" x="161.4" style="fill:rgb(19,20,19);font-family:PmpdftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">–</text>
  <text svgx:width="0.48,0.48,0.17" y="266.3" x="165.0,168.4,171.8" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">38.</text>
  <text svgx:width="0.48,0.48,0.17,0.55,0.54,0.21,0.53,0.53,0.54,0.55,0.53,0.17,0.55,0.46,0.54,0.48,0.29,0.48,0.21,0.45,0.42,0.21,0.36,0.55,0.63,0.17,0.55,0.5,0.48,0.54,0.52,0.21,0.45,0.3,0.21,0.53,0.53,0.55,0.53,0.26,0.55,0.45,0.29,0.3,0.44,0.54,0.48,0.55,0.44,0.45,0.21,0.44,0.21,0.52,0.81,0.55,0.44,0.53,0.45,0.53,0.53,0.48,0.21,0.36,0.55,0.53,0.26,0.55,0.45,0.45,0.36,0.44,0.52,0.21,0.45,0.29" y="275.4" x="56.7,60.1,63.5,64.8,71.7,75.6,77.1,80.8,84.6,88.7,90.6,94.4,95.7,97.7,100.9,104.8,108.2,110.3,113.7,115.2,118.4,121.3,122.8,125.5,127.6,132.1,133.4,135.4,139.0,142.4,146.3,150.0,151.5,154.6,156.8,158.3,162.1,166.0,168.0,171.8,173.7,175.7,178.9,181.0,183.2,186.3,190.1,193.7,195.7,198.8,202.0,203.5,206.6,208.1,211.8,217.9,219.7,222.9,226.6,229.8,233.6,237.4,240.8,242.3,245.0,247.0,250.8,252.7,254.8,258.0,261.1,263.7,266.9,270.6,272.0,275.2" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">93. Xiong Z, Sperelakis N. Regulation of L-type calcium channels of vascular</text>
  <text svgx:width="0.36,0.81,0.53,0.53,0.3,0.53,0.55,0.81,0.52,0.36,0.44,0.21,0.48,0.55,0.44,0.48,0.21,0.21,0.36,0.17,0.55,0.34,0.55,0.77,0.53,0.21,0.55,0.56,0.48,0.21,0.21,0.55,0.56,0.45,0.29,0.54,0.21,0.53,0.21,0.17,0.55,0.48,0.48,0.48,0.48,0.17,0.48,0.48,0.26,0.48,0.26,0.17,0.48,0.48" y="284.3" x="71.7,74.3,80.1,83.9,87.7,89.8,93.8,95.7,101.5,105.2,107.8,110.9,112.4,116.0,118.0,121.1,124.5,126.0,127.5,130.1,131.3,133.4,135.9,137.9,143.4,147.2,148.8,150.9,154.9,158.3,159.8,161.3,163.4,167.4,170.6,172.7,176.5,178.0,181.8,183.3,184.5,186.6,190.0,193.4,196.8,200.2,201.4,204.8,208.2,210.1,213.5,215.4,216.5,219.9" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">smooth muscle cells. J Mol Cell Cardiol. 1995;27(1):75</text>
  <text svgx:width="0.5" y="284.3" x="223.4" style="fill:rgb(19,20,19);font-family:PmpdftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">–</text>
  <text svgx:width="0.48,0.48,0.17" y="284.3" x="226.9,230.4,233.8" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">91.</text>
  <text svgx:width="0.48,0.48,0.17,0.55,0.5,0.21,0.44,0.53,0.45,0.29,0.54,0.55,0.46,0.17,0.55,0.5,0.45,0.36,0.44,0.52,0.21,0.45,0.29,0.55,0.48,0.26,0.26,0.48,0.44,0.3,0.36,0.55,0.53,0.26,0.55,0.44,0.45,0.21,0.44,0.21,0.52,0.81,0.55,0.44,0.53,0.45,0.53,0.53,0.48,0.21,0.55,0.45,0.53,0.3,0.45,0.54,0.53,0.53,0.21,0.36,0.3,0.36,0.17,0.55,0.53,0.48,0.72,0.55,0.48,0.45,0.21,0.54,0.48,0.53,0.44,0.48,0.17" y="293.3" x="56.7,60.1,63.5,64.8,71.7,75.3,76.8,79.9,83.7,86.8,88.9,93.0,94.9,98.2,99.4,101.5,105.0,108.2,110.8,113.9,117.6,119.1,122.3,124.5,126.5,130.0,131.8,133.7,137.1,140.2,142.3,145.0,147.1,150.8,152.8,154.9,158.0,161.2,162.7,165.8,167.3,171.0,177.0,178.9,182.0,185.8,188.9,192.7,196.5,199.9,201.5,203.6,206.8,210.6,212.7,215.9,219.7,223.5,227.3,228.8,231.4,233.5,236.1,237.4,239.5,243.3,246.7,252.1,253.9,257.3,260.5,262.0,265.9,269.3,273.1,276.2,279.6" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">94. Richard S. Vascular effects of calcium channel antagonists: new evidence.</text>
  <text svgx:width="0.64,0.29,0.52,0.54,0.36,0.17,0.55,0.48,0.48,0.48,0.48,0.17,0.48,0.48,0.26,0.48,0.26,0.17,0.48" y="302.3" x="71.7,76.3,78.4,82.1,85.9,88.5,89.8,91.8,95.3,98.7,102.1,105.5,106.7,110.1,113.5,115.4,118.8,120.6,121.8" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">Drugs. 2005;65(2):1</text>
  <text svgx:width="0.5" y="302.3" x="125.2" style="fill:rgb(19,20,19);font-family:PmpdftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">–</text>
  <text svgx:width="0.48,0.48,0.17" y="302.3" x="128.8,132.2,135.6" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">10.</text>
  <text svgx:width="0.48,0.48,0.17,0.55,0.58,0.54,0.45,0.44,0.53,0.21,0.55,0.46,0.17,0.55,0.77,0.53,0.54,0.52,0.21,0.45,0.3,0.21,0.53,0.53,0.55,0.53,0.26,0.55,0.45,0.45,0.36,0.44,0.52,0.21,0.45,0.29,0.55,0.36,0.45,0.29,0.44,0.53,0.34,0.48,0.53,0.54,0.53,0.54,0.21,0.45,0.36,0.81,0.21,0.44,0.55,0.29,0.48,0.3,0.21,0.44,0.52,0.21,0.52,0.81,0.55,0.44,0.45,0.21,0.44,0.21,0.52,0.81" y="311.4" x="56.7,60.1,63.5,64.8,71.7,75.9,79.7,82.9,86.0,89.8,91.4,93.4,96.7,98.0,100.0,105.5,109.3,113.1,116.8,118.3,121.5,123.7,125.1,128.9,132.9,134.9,138.7,140.6,142.6,145.8,149.0,151.6,154.7,158.4,159.9,163.1,165.3,167.3,169.9,173.1,175.2,178.3,182.0,184.5,187.9,191.7,195.5,199.3,203.2,204.7,207.8,210.4,216.2,217.7,221.0,223.0,225.1,228.5,230.7,232.1,235.3,239.0,240.4,244.2,250.2,252.1,255.2,258.4,259.9,263.0,264.5,268.2" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">95. Adachi T. Modulation of vascular sarco/endoplasmic reticulum calcium</text>
  <text svgx:width="0.58,0.46,0.5,0.45,0.36,0.48,0.55,0.21,0.53,0.55,0.44,0.45,0.29,0.54,0.21,0.53,0.45,0.45,0.36,0.44,0.52,0.21,0.45,0.29,0.55,0.54,0.45,0.3,0.53,0.53,0.54,0.53,0.44,0.36,0.21,0.53,0.21,0.53,0.54,0.44,0.17,0.55,0.58,0.54,0.45,0.55,0.5,0.53,0.45,0.29,0.81,0.45,0.44,0.53,0.21,0.17,0.55,0.48,0.48,0.48,0.48,0.17,0.48,0.48,0.17,0.48,0.48,0.48" y="320.3" x="71.7,75.9,79.1,82.7,85.9,88.5,92.1,94.0,95.5,99.5,101.4,104.5,107.7,109.8,113.6,115.1,118.9,122.1,125.3,127.9,131.0,134.7,136.2,139.4,141.5,143.6,147.5,150.6,152.8,156.6,160.4,164.2,168.0,171.1,173.7,175.2,179.0,180.5,184.2,188.1,191.2,192.5,194.6,198.7,202.6,206.0,207.9,211.5,215.2,218.4,220.5,226.3,229.5,232.6,236.4,237.8,239.1,241.2,244.6,248.1,251.5,254.9,256.1,259.5,262.9,264.1,267.5,270.9" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">ATPase in cardiovascular pathophysiology. Adv Pharmacol. 2010;59:165</text>
  <text svgx:width="0.5" y="320.3" x="274.3" style="fill:rgb(19,20,19);font-family:PmpdftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">–</text>
  <text svgx:width="0.48,0.48,0.17" y="320.3" x="277.9,281.3,284.7" style="fill:rgb(19,20,19);font-family:YfhhftAdvTTb5929f4c;font-size:7.5px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">95.</text>
  <text svgx:width="0.39" y="639.7" x="323.7" style="fill:rgb(19,20,19);font-family:SnncnfOpenSans-Extrabold;font-size:7.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">•</text>
  <text svgx:width="0.89,0.55,0.26,0.53,0.47,0.47,0.55,0.6,0.34,0.26,0.6,0.39,0.55,0.32,0.47,0.59,0.6,0.88,0.23,0.47,0.47,0.23,0.59,0.59,0.26,0.23,0.59,0.6,0.59,0.23,0.39,0.23,0.55,0.47" y="639.7" x="330.1,336.3,340.2,342.0,345.7,349.0,352.3,356.2,360.4,362.7,364.5,368.7,371.4,375.3,377.5,380.8,384.9,389.1,395.2,396.8,400.1,403.3,404.9,409.0,413.2,415.0,416.6,420.7,424.9,429.0,430.6,433.3,434.9,438.7" style="fill:rgb(41,40,41);font-family:VfpwxsOpenSans-Light;font-size:7.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">We accept pre-submission inquiries</text>
  <text svgx:width="0.39" y="651.7" x="323.7" style="fill:rgb(19,20,19);font-family:SnncnfOpenSans-Extrabold;font-size:7.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">•</text>
  <text svgx:width="0.76,0.59,0.39,0.26,0.47,0.55,0.23,0.55,0.47,0.34,0.59,0.39,0.26,0.34,0.59,0.59,0.23,0.26,0.59,0.55,0.23,0.6,0.47,0.26,0.46,0.59,0.59,0.26,0.34,0.59,0.26,0.53,0.59,0.6,0.26,0.34,0.59,0.55,0.26,0.88,0.59,0.47,0.34,0.26,0.39,0.55,0.23,0.55,0.46,0.53,0.59,0.34,0.26,0.23,0.59,0.59,0.39,0.59,0.53,0.23" y="651.7" x="330.1,335.4,339.6,342.3,344.1,347.4,351.2,352.8,356.6,360.0,362.3,366.4,369.1,370.9,373.3,377.4,381.5,383.1,384.9,389.0,392.9,394.5,398.6,401.9,403.7,406.9,411.0,415.1,417.0,419.3,423.4,425.2,428.9,433.0,437.2,439.0,441.4,445.5,449.3,451.2,457.3,461.4,464.7,467.1,468.9,471.6,475.4,477.0,480.9,484.1,487.8,491.9,494.3,496.1,497.7,501.8,505.9,508.6,512.8,516.5" style="fill:rgb(41,40,41);font-family:VfpwxsOpenSans-Light;font-size:7.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">Our selector tool helps you to ﬁnd the most relevant journal</text>
  <text svgx:width="0.39,0.26,0.26" y="663.7" x="323.7,326.4,328.3" style="fill:rgb(19,20,19);font-family:SnncnfOpenSans-Extrabold;font-size:7.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">• </text>
  <text svgx:width="0.89,0.55,0.26,0.6,0.39,0.59,0.46,0.23,0.6,0.55,0.26,0.39,0.59,0.59,0.59,0.6,0.26,0.34,0.59,0.55,0.26,0.47,0.23,0.59,0.47,0.48,0.26,0.47,0.59,0.47,0.34,0.59,0.88,0.55,0.39,0.26,0.47,0.59,0.6,0.6,0.59,0.39,0.34,0.26" y="663.7" x="330.1,336.3,340.2,342.0,346.2,348.9,353.0,356.2,357.8,361.9,365.8,367.6,370.3,374.4,378.6,382.7,386.8,388.7,391.0,395.1,399.0,400.8,404.1,405.7,409.8,413.1,416.5,418.3,421.7,425.8,429.1,431.4,435.5,441.7,445.5,448.3,450.1,453.3,457.5,461.6,465.8,469.9,472.6,475.0" style="fill:rgb(41,40,41);font-family:VfpwxsOpenSans-Light;font-size:7.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">We provide round the clock customer support </text>
  <text svgx:width="0.39,0.26,0.26" y="675.7" x="323.7,326.4,328.3" style="fill:rgb(19,20,19);font-family:SnncnfOpenSans-Extrabold;font-size:7.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">• </text>
  <text svgx:width="0.62,0.59,0.59,0.46,0.55,0.59,0.23,0.55,0.59,0.34,0.26,0.59,0.59,0.23,0.23,0.59,0.55,0.26,0.47,0.59,0.6,0.88,0.23,0.47,0.47,0.23,0.59,0.59" y="675.7" x="330.1,334.4,338.5,342.7,345.9,349.7,353.8,355.4,359.3,363.4,365.7,367.6,371.7,375.8,377.4,379.0,383.1,386.9,388.8,392.0,396.1,400.3,406.5,408.1,411.3,414.6,416.2,420.3" style="fill:rgb(41,40,41);font-family:VfpwxsOpenSans-Light;font-size:7.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">Convenient online submission</text>
  <text svgx:width="0.39" y="687.7" x="323.7" style="fill:rgb(19,20,19);font-family:SnncnfOpenSans-Extrabold;font-size:7.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">•</text>
  <text svgx:width="0.52,0.59,0.59,0.39,0.59,0.59,0.52,0.59,0.26,0.6,0.55,0.55,0.39,0.26,0.39,0.55,0.46,0.23,0.55,0.72" y="687.7" x="330.1,333.7,337.9,342.0,344.7,348.8,352.9,356.6,360.7,362.5,366.7,370.6,374.4,377.1,378.9,381.7,385.5,388.7,390.3,394.1" style="fill:rgb(41,40,41);font-family:VfpwxsOpenSans-Light;font-size:7.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">Thorough peer review</text>
  <text svgx:width="0.39,0.26,0.26" y="699.7" x="323.7,326.4,328.3" style="fill:rgb(19,20,19);font-family:SnncnfOpenSans-Extrabold;font-size:7.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">• </text>
  <text svgx:width="0.25,0.59,0.47,0.23,0.59,0.47,0.23,0.59,0.59,0.26,0.23,0.59,0.26,0.58,0.59,0.6,0.86,0.55,0.6,0.26,0.53,0.59,0.6,0.26,0.53,0.23,0.23,0.26,0.88,0.53,0.23,0.59,0.39,0.26,0.23,0.59,0.6,0.55,0.5,0.23,0.59,0.52,0.26,0.47,0.55,0.39,0.46,0.23,0.47,0.55,0.47,0.26" y="699.7" x="330.1,331.8,336.0,339.3,340.9,345.0,348.3,349.9,354.0,358.1,359.9,361.5,365.6,367.4,371.5,375.7,379.8,385.9,389.7,393.9,395.7,399.4,403.5,407.7,409.5,413.2,414.8,416.4,418.2,424.4,428.1,429.7,433.8,436.5,438.3,439.9,444.0,448.2,452.1,455.5,457.1,461.3,464.9,466.7,470.0,473.8,476.6,479.8,481.4,484.7,488.5,491.8" style="fill:rgb(41,40,41);font-family:VfpwxsOpenSans-Light;font-size:7.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">Inclusion in PubMed and all major indexing services </text>
  <text svgx:width="0.39" y="711.7" x="323.7" style="fill:rgb(19,20,19);font-family:SnncnfOpenSans-Extrabold;font-size:7.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">•</text>
  <text svgx:width="0.86,0.53,0.5,0.23,0.88,0.59,0.88,0.26,0.46,0.23,0.47,0.23,0.6,0.23,0.23,0.23,0.34,0.46,0.26,0.3,0.59,0.39,0.26,0.46,0.59,0.59,0.39,0.26,0.39,0.55,0.47,0.55,0.53,0.39,0.47,0.59" y="711.7" x="330.1,336.1,339.8,343.3,344.9,351.1,355.2,361.4,363.2,366.4,368.0,371.3,372.8,377.0,378.6,380.2,381.8,384.1,387.3,389.1,391.2,395.3,398.1,399.9,403.1,407.2,411.3,414.1,415.9,418.6,422.4,425.7,429.5,433.3,436.0,439.3" style="fill:rgb(41,40,41);font-family:VfpwxsOpenSans-Light;font-size:7.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">Maximum visibility for your research</text>
  <text svgx:width="0.55,0.59,0.6,0.88,0.23,0.34,0.26,0.46,0.59,0.59,0.39,0.26,0.88,0.53,0.59,0.59,0.47,0.47,0.39,0.23,0.6,0.34,0.26,0.53,0.34" y="728.5" x="323.7,327.5,331.6,335.8,342.0,343.6,345.9,347.7,350.9,355.1,359.2,361.9,363.7,369.9,373.6,377.7,381.9,385.1,388.5,391.2,392.8,396.9,399.3,401.1,404.8" style="fill:rgb(41,40,41);font-family:VfpwxsOpenSans-Light;font-size:7.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">Submit your manuscript at</text>
  <text svgx:width="0.72,0.72,0.72,0.24,0.6,0.23,0.59,0.88,0.55,0.6,0.47,0.55,0.59,0.34,0.39,0.53,0.23,0.24,0.47,0.59,0.88,0.34,0.47,0.59,0.6,0.88,0.23,0.34" y="736.5" x="323.7,328.8,333.8,338.9,340.5,344.7,346.3,350.4,356.6,360.4,364.6,367.9,371.8,375.9,378.2,381.0,384.7,386.2,387.9,391.2,395.3,401.5,403.9,407.2,411.3,415.5,421.6,423.2" style="fill:rgb(41,40,41);font-family:VfpwxsOpenSans-Light;font-size:7.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">www.biomedcentral.com/submit</text>
  <text svgx:width="0.47,0.49,0.51,0.78,0.16,0.28,0.28,0.49,0.55,0.49,0.29,0.28,0.48,0.5,0.52,0.28,0.28,0.78,0.48,0.48,0.49,0.37,0.48,0.29,0.16,0.51,0.28,0.28,0.28,0.55,0.28,0.52,0.16,0.55,0.86,0.5,0.51,0.28,0.65,0.5,0.48,0.28,0.29,0.48,0.17,0.28" y="611.7" x="318.4,323.6,328.9,334.5,343.0,344.7,347.9,350.9,356.3,362.3,367.6,370.8,373.9,379.2,384.7,390.4,393.5,396.5,405.1,410.3,415.6,421.0,425.0,430.4,433.6,435.3,440.9,444.0,447.1,450.2,456.2,459.3,465.0,466.7,472.7,482.2,487.7,493.3,496.3,503.5,509.0,514.3,517.4,520.6,525.9,527.7" style="fill:rgb(19,20,19);font-family:XtdgwgOregonLDOBook;font-size:11.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">Submit your next manuscript to BioMed Central </text>
  <text svgx:width="0.48,0.48,0.51,0.28,0.79,0.5,0.28,0.79,0.16,0.17,0.17,0.28,0.46,0.5,0.17,0.51,0.28,0.49,0.55,0.49,0.28,0.48,0.28,0.28,0.5,0.49,0.5,0.29,0.49,0.28,0.37,0.28,0.5,0.51,0.19" y="624.9" x="318.4,323.6,329.0,334.5,337.6,346.3,351.8,354.8,363.6,365.3,367.1,369.0,372.0,377.1,382.5,384.4,390.0,393.0,398.4,404.4,409.8,412.8,418.0,421.2,424.2,429.7,435.1,440.5,443.7,449.1,452.1,456.2,459.3,464.8,470.4" style="fill:rgb(19,20,19);font-family:XtdgwgOregonLDOBook;font-size:11.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">and we will help you at every step:</text>
  <text svgx:width="0.66,0.23,0.56" y="39.0" x="56.7,61.9,63.8" style="fill:rgb(19,20,19);font-family:NjjblyAdvTTe45e47d2;font-size:8.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">Dib</text>
  <text svgx:width="0.45,0.31,0.55,0.52,0.22,0.21,0.55,0.51,0.77,0.55,0.55,0.55,0.52,0.8,0.52,0.22,0.45,0.8,0.45,0.53,0.31,0.52,0.31,0.44,0.55,0.52,0.53,0.52,0.55,0.56,0.22,0.31,0.45,0.31,0.53,0.52,0.31,0.22,0.45,0.45,0.55,0.77,0.45,0.52,0.22,0.42,0.22,0.53,0.45" y="39.0" x="70.6,74.2,76.7,79.1,83.2,85.0,86.7,89.1,93.1,99.3,103.7,106.1,110.5,114.6,121.1,125.2,127.0,130.5,137.0,140.5,144.8,147.2,151.3,153.8,157.4,159.8,163.9,168.2,172.3,174.7,179.2,180.9,183.4,187.0,189.5,193.7,197.9,200.4,202.1,205.7,209.3,211.6,217.8,221.4,225.5,227.3,230.6,232.3,236.6" style="fill:rgb(19,20,19);font-family:GnxlbsAdvTT7329fd89.I;font-size:8.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">et al. BMC Complementary and Alternative Medicine</text>
  <text svgx:width="0.21,0.28,0.51,0.51,0.51,0.51,0.28,0.21,0.51,0.51,0.21,0.51,0.51,0.21" y="39.0" x="242.5,244.2,246.5,250.6,254.7,258.8,262.9,265.2,266.9,271.0,275.1,276.7,280.9,285.0" style="fill:rgb(19,20,19);font-family:MyriadPro-Regular;font-size:8.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx"> (2017) 17:82 </text>
  <text svgx:width="0.53,0.48,0.55,0.5,0.55,0.51,0.51,0.55,0.54,0.29,0.55,0.51,0.51" y="39.0" x="492.0,496.2,500.1,504.5,508.5,510.9,514.9,519.0,521.4,525.7,528.1,530.4,534.5" style="fill:rgb(19,20,19);font-family:NjjblyAdvTTe45e47d2;font-size:8.0px;stroke:none;" xmlns:svgx="http://www.xml-cml.org/schema/svgx">Page 15 of 15</text>
 </g>
</svg>
